Mikoflyukan

General characteristics. Structure:

1 tablet contains 50 mg or 150 mg of a flukonazol.
Excipients: microcrystallic cellulose, lactose, kroskarmelloza, povidone, silicon dioxide, magnesium stearate, talc.
Description:
Tablets "150"
White or almost white, round tablets, flat with slanted edges, with impression of "F150" on one party and dividing risky on other party.

Pharmacological properties:

Pharmacodynamics. Flukonazol is the representative of a class of triazolny antifungal means, is powerful selection inhibitor of synthesis of sterol in a cell of mushrooms. Drug is effective at opportunistic mycoses, including the caused Candida spp., Cryptococcus neoformans, Microsporum spp., Trichophyton spp. Also activity of a flukonazol on models of endemic mycoses, including infections the caused Biastomyces dermatitides is shown, to Coccidiodes immitis and Histoplasma capsulatum.

Indications to use:

Cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), as at patients with a normal immune response, and at patients with various forms of immunosuppression (including patients have AIDS, at organ transplantation); drug can be used as means of a maintenance therapy for prevention of a cryptococcal infection at patients AIDS;
 generalized candidiasis, including a kandidemiya, the disseminated candidiasis and other forms of invasive candidosis infections (an infection of a peritoneum, an endocardium, eyes, respiratory and uric ways). Treatment can be carried out at patients with malignant new growths, sick intensive care units, the patients taking a course of cytostatic or immunosuppressive therapy and also in the presence of other factors contributing to development of candidiasis; candidiasis of mucous membranes, including oral cavities and drinks, a gullet, noninvasive bronchopulmonary candidiases, a kandiduriya, candidiases of skin and mucous membranes, and also the atrophic candidiasis of an oral cavity connected with carrying dentures (treatment can be carried out at patients with the normal or lowered immunity function); prevention of a recurrence of oropharyngeal candidiasis at patients AIDS;
genital candidiasis: vaginal candidiasis (acute and chronic recuring), preventive use for the purpose of reduction of frequency of a recurrence of vaginal candidiasis (3 and more episodes a year); candidosis balanitis;
prevention of fungal infections at patients with malignant new growths which are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy;
skin mycoses, including mycoses of feet, bodies, inguinal area; chromophytosis; onychomycosis; skin candidiasis;
deep local mycoses, including кокцидиомикоз, паракокцидиомикоз, a sporotrichosis and histoplasmosis at patients with normal immunity.

Route of administration and doses:

The adult at cryptococcal meningitis and cryptococcal infections of other localizations in the first day usually appoint 400 mg, and then continue treatment in a dose of 200-400 mg of 1 times/days. Treatment duration at cryptococcal infections depends on the clinical performance confirmed with a mycologic research; at cryptococcal meningitis it is usually continued at least by 6-8 weeks.
For prevention of a recurrence of cryptococcal meningitis at patients AIDS, after end of a full course of primary treatment, флуконазол appoint in a dose 200 mg/days during a long span.

At a kandidemiya, the disseminated candidiasis and other invasive candidosis infections the dose usually makes 400 mg in the first days, and then - on 200 mg. At insufficient clinical performance the dose of drug can be increased to 400 mg/days. Duration of therapy depends on clinical performance.

At oropharyngeal candidiasis drug is usually appointed on 50-100 mg of 1 times/days; treatment duration - 7-14 days. If necessary, at patients with the expressed decrease in immunity treatment can be longer.

At the atrophic candidiasis of an oral cavity connected with carrying dentures флуконазол usually appoint on 50 mg of 1 times/days within 14 days in combination with local antiseptic agents for processing of a prosthesis.

At other localizations of candidiasis (except for genital candidiasis), for example at an esophagitis, noninvasive bronchopulmonary damage, a kandiduriya, candidiasis of skin and mucous membranes, etc., the effective dose usually makes 50-100 mg/days lasting treatment of 14-30 days. For prevention of a recurrence of oropharyngeal candidiasis at patients about AIDS after end of a full course of primary therapy drug can be appointed on 150 mg once a week.
At vaginal candidiasis флуконазол accept once inside in a dose 150 mg. For decrease in frequency of a recurrence of vaginal candidiasis drug can be used in a dose of 150 mg of 1 times in month. Duration of therapy is determined individually; it varies from 4 to 12 months. More frequent use can be required by some patients.

At the balanitis caused by Candida флуконазол appoint once in a dose 150 mg inside.
For prevention of candidiasis the recommended dose флуконазол makes 50-400 mg of 1 times/days depending on a risk degree of development of a fungal infection. With high risk of a generalized infection, for example at patients from the expected expressed or it is long the remaining neutropenia, the recommended dose

Flukonazol makes 400 mg of 1 time/days appoint some days before the expected emergence of a neutropenia; after increase in number of neutrophils more than 1000/mm 3rd treatment is continued within 7 days.

At skin mycoses, including mycoses of feet, skin of inguinal area, and skin candidiases the recommended dose makes 150 mg once a week or 50 mg of 1 times/days. Therapy duration in everyday occurences makes 2-4 weeks, however at mycoses of feet longer therapy can be required (up to 6 weeks).

At a chromophytosis the recommended dose makes 300 mg within 2 weeks once a week. Some patients need the third dose of 300 mg a week while regarding cases it is sufficient a single dose of 300-400 mg. The alternative scheme of treatment is use of drug on 50 mg of 1 times/days within 2-4 weeks.

At an onychomycosis the recommended dose makes 150 mg once a week. Treatment should be continued before substitution of the infected nail (growth of not infected nail). Repeated growth of nails on fingers of hands and feet normal requires 3-6 months and 6-12 months according to.

At deep local mycoses use of drug in a dose of 200-400 mg/days during up to 2 years can be required. Duration of therapy is determined individually; it can make 11-24 months at a koktsidiomikoza; 2-17 months at a parakoktsidiomikoza; 1-16 months at a sporotrichosis and 3-17 months at histoplasmosis.

At children, as well as at similar infections at adults, duration of treatment depends on clinical and mycologic effect. At children drug should not be used in a daily dose which would exceed that at adults. Drug is used daily by 1 times/days.

At candidiasis of mucous membranes the recommended dose of a flukonazol makes 3 mg/kg/days. In the first day the shock dose of 6 mg/kg for the purpose of more bystry achievement of constant equilibrium concentration can be appointed.

For treatment of generalized candidiasis or a cryptococcal infection the recommended dose makes 6-12 mg/kg/days depending on disease severity. For prevention of fungal infections at children with reduced immunity at which the risk of development of an infection is connected with the neutropenia developing as a result of cytotoxic chemotherapy or radiation therapy drug is appointed on 3-12 mg/kg/days depending on expressiveness and duration of preservation of the induced neutropenia.

At children with renal failures the daily dose of drug should be reduced (in the same proportional dependence, as at adults), according to degree of manifestation of a renal failure.

At newborns флуконазол it is removed slowly. In the first 2 weeks of life drug is appointed in the same dose (in mg/kg), as at children of more advanced age, but with an interval of 72 h. To children at the age of 2-4 weeks the same dose is entered with an interval of 48 h.

At patients of advanced age in the absence of renal failures it is necessary to adhere to the usual mode of a drug dosing. Patients with a renal failure (clearance of creatinine less than 50 ml/min.) should correct the mode of dosing, as shown below.

Use of drug for patients with renal failures. Flukonazol is brought generally with urine in not changed look. At its single dose change of a dose is not required. At repeated purpose of drug patients with an impaired renal function should enter at first a shock dose from 50 mg to 400 mg. If the clearance of creatinine (CC) makes more than 50 ml/min., the usual dose of drug (100% of the recommended dose) is applied. At KK from 11 to 50 ml/min. the dose equal of 50% recommended is applied. The patient who is regularly on dialysis, one dose of drug is applied after each session of a hemodialysis.

Features of use:

In rare instances use of a flukonazol was followed by toxic changes of a liver, including with a lethal outcome, mainly at patients with serious associated diseases. In case of the hepatotoxic effects connected with flukonazoly explicit dependence them from the general daily dose, duration of therapy, a floor, and age of the patient is noted. The hepatotoxic action of a flukonazol usually was reversible; its signs disappeared after the therapy termination. At emergence of clinical signs of damage of a liver which can be connected with flukonazoly drug should be cancelled.

Patients AIDS are more inclined to development of heavy skin reactions at use of many drugs. When at patients with a superficial fungal infection rash develops and it is regarded as definitely connected with flukonazoly, drug should be cancelled. At emergence of rash in patients with invasive/system fungal infections, they should be observed and cancelled carefully флуконазол at emergence of violent changes or a mnogoformny erythema.
It is necessary to be careful at a concomitant use of a flukonazol with tsizapridy, astemizoly, rifabutiny, takrolimusy or other drugs which are metabolized system of P 450 cytochrome.

Side effects:

From a GIT: often - nausea, an abdominal pain, diarrhea, a meteorism. Dermatological reactions: often - skin rash. From TsNS: headache.
At some patients, especially with such diseases as AIDS or malignant new growths, during treatment flukonazoly changes of indicators of blood, an abnormal liver function and kidneys can be observed.

Exfoliative skin diseases (Stephens-Johnson's syndrome and toxic epidermal necrolysis), spasms, leukopenia, thrombocytopenia and alopecia can take place.
Exceptional cases of anaphylactic reactions are known, as well as at reception of other azoles.

Interaction with other medicines:

At use of a flukonazol with warfarin the prothrombin time increases, (on average by 12%). In this regard it is recommended to watch carefully indicators of a prothrombin time at the patients receiving drug in combination with coumarinic anticoagulants.
Flukonazol increases plasma elimination half-life of peroral gipoglikemiziruyushchy means - sulphonylurea derivatives (a chlorpropanide, Glibenclamidum, глипизид, Tolbutamidum) at healthy people. Combined use of Flukonazol and peroral gipoglikemiziruyushchy means at patients with diabetes is allowed, however the doctor has to mean a possibility of development of a hypoglycemia.
Simultaneous use of Flukonazol and Phenytoinum can lead to increase of concentration of Phenytoinum in plasma to clinically significant degree. Therefore in need of combined use of these drugs it is necessary to monitorirovat concentration of Phenytoinum with correction of its dose for the purpose of maintenance of level of drug within a therapeutic interval.
The combination with rifampicin leads to decrease in AUC by 25% and shortening of an elimination half-life of a flukonazol from plasma for 20%. Therefore the patient receiving at the same time rifampicin, it is reasonable to increase Flukonazol's dose.
It is recommended to exercise control of concentration of cyclosporine in blood at patients, receiving Flukonazol as use of a flukonazol and cyclosporine for patients with the replaced kidney leads Flukonazol's reception in a dose of 200 mg/days to slow increase in concentration of cyclosporine in plasma.
Patients who receive high doses of theophylline or who have a probability of development of teofillinovy intoxication have to be under observation for the purpose of early identification of symptoms of overdose of theophylline as reception of a flukonazol leads to decrease in average speed of clearance of theophylline from plasma.
At simultaneous use Flukonazol and a tsizaprida cases of undesirable reactions from heart are described, including paroxysms of ventricular tachycardia (torsades de points).
There are messages on interaction of the flukonazol and a rifabutin which was followed by increase in serumal levels of the last. At simultaneous use of Flukonazol and a rifabutin uveitis cases are described. It is necessary to observe carefully the patients who are at the same time receiving рифабутин and флуконазол.
At simultaneous use of Flukonazol and a takrolimus nephrotoxicity cases are described. It is necessary to observe carefully the patients who are at the same time receiving такролимус and флуконазол.
At the patients receiving a combination of a flukonazol and zidovudine increase in concentration of a zidovudine which is caused by decrease in transformation of the last into its main metabolite therefore it is necessary to expect increase in side effects of a zidovudine is observed.

Contraindications:

Concomitant use of a terfenadin or astemizol
hypersensitivity to drug or relatives on structure to azolny connections

Pregnancy and lactation
Use of drug for pregnant women is inexpedient, except for severe or life-threatening forms of fungal infections if the estimated effect exceeds possible risk for a fruit.
Flukonazol is in breast milk in the same concentration, as well as in plasma therefore its appointment in the period of a lactation is not recommended.

Overdose:

In case of overdose the symptomatic treatment (including the supporting measures and a gastric lavage) can give adequate effect.

Flukonazol is brought generally with urine therefore the artificial diuresis, can accelerate drug removal. After the 3-hour session of a hemodialysis concentration of a flukonazol in plasma decreases approximately by 50%.

Storage conditions:

In the dry, protected from light place at a temperature not above 25 °C, in the places unavailable to children.
Period of validity 3 years. Not to use after the expiry date specified on packaging.

Issue conditions:

Without recipe

Packaging:

Tablets on 50 and 150 mg. In the tablet blister 1 or 4.